Renalytix plc
("Renalytix" or the "Company")
Grant & Cancellation of Options / PDMR Dealings
Name |
Position |
Options granted |
|
|
|
James McCullough |
Chief Executive Officer |
9,638,095 |
Julian Baines |
Executive Chairman |
6,425,397 |
Fergus Fleming |
Chief Technology Officer & Executive Director |
5,782,857 |
Howard Doran |
President |
4,819,047 |
Catherine Coste1 |
Non-Executive Director |
1,285,079 |
Joel Jung2 |
Interim Chief Financial Officer |
963,809 |
The Options, which have been issued in line with the Company's existing share option plan, have an exercise price of £0.0996 per ordinary share, being the closing mid-market price of the shares on 23 December 2024.
The Options for the Executive Directors above will vest as follows:
· One third upon the Company achieving a mid-market share price of
· One third upon the Company achieving
· One third vesting quarterly over 36 months on a quarterly basis.
All Options are subject to the individuals remaining employed by the Company and will only vest after a six month cliff from the vesting commencement date.
The Board recognises the importance of share options to appropriately incentivise and retain staff as well as to ensure their interests are aligned with that of the Company and its shareholders. Therefore, the Remuneration Committee recommended to the Board that, given the prevailing share price of the Company and the increase in its issued share capital following the fundraise announced on 30 September 2024, the existing awards of share options ("Existing Options") were no longer a reasonable incentive. As such, it was proposed that the Existing Options be cancelled and replaced by the Options to re-align the option scheme with the current share price and issued share capital of the Company. Consequently, 2,811,080 Existing Options held by certain directors and PDMRs were cancelled on 24 December 2024, as detailed below. The holders of the Existing Options have agreed to their cancellation with immediate effect.
Name |
Position |
Options cancelled |
|
|
|
James McCullough |
Chief Executive Officer |
875,017 |
Julian Baines |
Executive Chairman |
- |
Fergus Fleming |
Chief Technology Officer & Executive Director |
891,063 |
Howard Doran |
President |
700,000 |
Catherine Coste1 |
Non-Executive Director |
285,000 |
Joel Jung2 |
Interim Chief Financial Officer |
60,000 |
1Catherine Coste's Options will vest equally on a quarterly basis over the one-year period from grant.
2Joel Jung's Options will vest equally on a quarterly basis over the six-month period until the end of his consulting term on 30 June 2025.
For further information, please contact:
Renalytix plc |
|
James McCullough, CEO |
Via Walbrook PR |
|
|
Stifel (Nominated Adviser and Joint Broker) |
Tel: 020 7710 7600 |
Nicholas Moore / Nick Harland / Ben Good |
|
|
|
Oberon Capital (Joint Broker) |
Tel: 020 3179 5300 |
Mike Seabrook / Nick Lovering |
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
Paul McManus / Alice Woodings |
Mob: 07980 541 893 / 07407 804 654 |
|
|
CapComm Partners |
|
Peter DeNardo
|
Tel: 415-389-6400 or investors@renalytix.com |
About Renalytix
Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in
Unrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in
The over 10,000 patients that have been tested by kidneyintelX.dkd have produced a substantial body of real-world performance data. In patient populations where kidneyintelX.dkd has been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded. kidneyintelX.dkd now has full reimbursement established by Medicare, the largest insurance payer in
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
a)
|
Name
|
James McCullough
|
|||
2
|
Reason for the notification
|
||||
a)
|
Position/status
|
Chief Executive Officer |
|||
b)
|
Initial notification /Amendment
|
Initial Notification |
|||
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
Renalytix plc |
|||
b)
|
LEI
|
213800NTOH3FK3WER551 |
|||
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
a)
|
Description of the financial instrument, type of instrument |
Ordinary shares of |
|||
|
|
||||
Identification code |
GB00BYWL4Y04
|
||||
|
|
||||
b)
|
Nature of the transaction
|
Grant of options over shares |
|||
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
9,638,095 |
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
||||
- Aggregated volume |
9,638,095 |
||||
- Price |
|
||||
|
|
||||
e)
|
Date of the transaction
|
24 December 2024 |
|||
f)
|
Place of the transaction
|
London Stock Exchange, AIM |
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
a)
|
Name
|
Julian Baines |
|||
2
|
Reason for the notification
|
||||
a)
|
Position/status
|
Executive Chairman |
|||
b)
|
Initial notification /Amendment
|
Initial Notification |
|||
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
Renalytix plc |
|||
b)
|
LEI
|
213800NTOH3FK3WER551 |
|||
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
a)
|
Description of the financial instrument, type of instrument |
Ordinary shares of |
|||
|
|
||||
Identification code |
GB00BYWL4Y04
|
||||
|
|
||||
b)
|
Nature of the transaction
|
Grant of options over shares |
|||
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
6,425,397 |
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
||||
- Aggregated volume |
6,425,397 |
||||
- Price |
£639,969.50 |
||||
|
|
||||
e)
|
Date of the transaction
|
24 December 2024 |
|||
f)
|
Place of the transaction
|
London Stock Exchange, AIM |
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
a)
|
Name
|
Fergus Fleming
|
|||
2
|
Reason for the notification
|
||||
a)
|
Position/status
|
Chief Technology Officer & Executive Director |
|||
b)
|
Initial notification /Amendment
|
Initial Notification |
|||
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
Renalytix plc |
|||
b)
|
LEI
|
213800NTOH3FK3WER551 |
|||
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
a)
|
Description of the financial instrument, type of instrument |
Ordinary shares of |
|||
|
|
||||
Identification code |
GB00BYWL4Y04
|
||||
|
|
||||
b)
|
Nature of the transaction
|
Grant of options over shares |
|||
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
5,782,857 |
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
||||
- Aggregated volume |
5,782,857 |
||||
- Price |
|
||||
|
|
||||
e)
|
Date of the transaction
|
24 December 2024 |
|||
f)
|
Place of the transaction
|
London Stock Exchange, AIM |
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
a)
|
Name
|
Howard Doran
|
|||
2
|
Reason for the notification
|
||||
a)
|
Position/status
|
President
|
|||
b)
|
Initial notification /Amendment
|
Initial Notification |
|||
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
Renalytix plc |
|||
b)
|
LEI
|
213800NTOH3FK3WER551 |
|||
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
a)
|
Description of the financial instrument, type of instrument |
Ordinary shares of |
|||
|
|
||||
Identification code |
GB00BYWL4Y04
|
||||
|
|
||||
b)
|
Nature of the transaction
|
Grant of options over shares |
|||
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
4,819,047 |
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
||||
- Aggregated volume |
4,819,047 |
||||
- Price |
|
||||
|
|
||||
e)
|
Date of the transaction
|
24 December 2024 |
|||
f)
|
Place of the transaction
|
London Stock Exchange, AIM |
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
a)
|
Name
|
Catherine Coste
|
|||
2
|
Reason for the notification
|
||||
a)
|
Position/status
|
Non-Executive Director |
|||
b)
|
Initial notification /Amendment
|
Initial Notification |
|||
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
Renalytix plc |
|||
b)
|
LEI
|
213800NTOH3FK3WER551 |
|||
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
a)
|
Description of the financial instrument, type of instrument |
Ordinary shares of |
|||
|
|
||||
Identification code |
GB00BYWL4Y04
|
||||
|
|
||||
b)
|
Nature of the transaction
|
Grant of options over shares |
|||
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
1,285,079 |
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
||||
- Aggregated volume |
1,285,079 |
||||
- Price |
|
||||
|
|
||||
e)
|
Date of the transaction
|
24 December 2024 |
|||
f)
|
Place of the transaction
|
London Stock Exchange, AIM |
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
a)
|
Name
|
Joel Jung
|
|||
2
|
Reason for the notification
|
||||
a)
|
Position/status
|
Interim Chief Financial Officer |
|||
b)
|
Initial notification /Amendment
|
Initial Notification |
|||
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
Renalytix plc |
|||
b)
|
LEI
|
213800NTOH3FK3WER551 |
|||
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
a)
|
Description of the financial instrument, type of instrument |
Ordinary shares of |
|||
|
|
||||
Identification code |
GB00BYWL4Y04
|
||||
|
|
||||
b)
|
Nature of the transaction
|
Grant of options over shares |
|||
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
963,809 |
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
||||
- Aggregated volume |
963,809 |
||||
- Price |
|
||||
|
|
||||
e)
|
Date of the transaction
|
24 December 2024 |
|||
f)
|
Place of the transaction
|
London Stock Exchange, AIM |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.